CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 56 enrolled
Drug / intervention
Cancer Macrobead placement in abdominal cavitybiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00283075
NCT00283075Phase 1Completed

Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer

The Rogosin Institute·interventional·Posted Jan 27, 2006·Updated Jan 16, 2019

In Brief

A Phase 1 clinical trial evaluating Cancer Macrobead placement in abdominal cavity for Intraabdominal Cancers (Various Types). Completed, enrolled 56 participants across 1 site.

Detailed Summary

This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer. The macrobeads have been extensively tested in tumor models in mice and rats, as well as in forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor responses and no significant detectable toxicity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2006
Enrollment StartJan 1, 2005
Primary CompletionDec 1, 2012
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 20.4 years ago

Interventions

Cancer Macrobead placement in abdominal cavitybiological

8 macrobeads per kg